MedTrace Logo

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

NCT04316013 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 254

Last updated 2025-03-14

No results posted yet for this study

Summary

VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus no lidocaine on duration of disease free survival inpatients with either colorectal or non small cell lung cancer.

Conditions

Interventions

DRUG

Sevoflurane

Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice

DRUG

Propofol

Intravenous anaesthetic used for induction and maintenance of anaesthesia

DRUG

Lidocaine IV

1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Australian and New Zealand College of Anaesthetists

    collaborator OTHER

  • Victorian Comprehensive Cancer Centre

    collaborator UNKNOWN

  • Peter MacCallum Cancer Centre, Australia

    lead OTHER

Principal Investigators

  • Bernhard Riedel, MB.ChB · Peter MacCallum Cancer Centre, Australia

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2025-02-28
Completion
2025-02-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04316013 on ClinicalTrials.gov